ICH E6(R3) Annex 2 Was Adopted in June 2026 and Applies in the EU from January 2027

ICH E6 is the international standard for Good Clinical Practice in trials of medicinal products. The third revision, E6(R3), replaces E6(R2), the 2016 version, and is organised into overarching Principles and a set of annexes. The Principles and Annex 1 were adopted by ICH on 6 January 2025. Annex 1 sets out the detailed GCP expectations that apply to interventional clinical trials of investigational products, building on the Principles. Together they replace the earlier, more prescriptive structure of E6(R2) with an approach that places more weight on proportionality and on building quality into trial design.

Annex 2 was developed separately and adopted at ICH Step 4 on 3 June 2026. ICH has published a consolidated guideline in which the Step 4 document is combined with Annex 2; an ICH presentation on the Annex 2 Step 4 version carries the date 27 May 2026, which differs from the adoption date in the final text. Annex 2 provides additional considerations for trials that incorporate decentralised elements, pragmatic elements and real-world data, and it is intended to be read together with the Principles and Annex 1 rather than as a separate standard. Industry summaries report that the final Annex 2 made relatively few structural changes from the 2024 consultation draft, with added clarity on matters such as oversight of real-world data sources.

European Union. The European Medicines Agency announced in January 2025 that the Principles and Annex 1 would come into effect on 23 July 2025. For Annex 2, EMA reports adoption by the Committee for Medicinal Products for Human Use on 25 June 2026 and an effective date of 15 January 2027. One secondary source reports that the UK and Switzerland applied the same 23 July 2025 date for the Principles and Annex 1.

United States. The Food and Drug Administration published E6(R3) as final guidance in September 2025; sources give 8 September 2025 for the guidance and 9 September 2025 for the Federal Register notice. The guidance is non-binding and the underlying FDA regulations on human subject protection, institutional review boards and investigational new drug applications are unchanged. For Annex 2, a secondary source reported that the FDA web page still described the Annex as a draft as of 19 September 2026. No FDA final guidance for Annex 2 could be confirmed for this brief.

Japan. PMDA materials state that E6(R3) is planned to be incorporated into the Japanese regulatory framework, including the GCP Ministerial Ordinance and related notifications, within fiscal year 2026. A specific effective date could not be confirmed at the time of checking.

China. A trade press report states that clinical trials beginning on or after 31 March 2026 are subject to E6(R3) in China, and that the National Medical Products Administration consulted in August 2026 on a proposed implementation date for Annex 2. This information comes from a secondary source and should be confirmed against NMPA notices.

For trials in the EU, the Principles and Annex 1 already apply, and quality management systems, monitoring plans and trial master file processes should be aligned with them. Sponsors should use the period before 15 January 2027 to review how trials that use remote consent, direct-to-participant shipment of investigational product, wearable devices, routine care data or registry data are designed and overseen, since these are the areas addressed by Annex 2.

For multinational programmes, the differing regional timelines matter. A trial could, for example, be expected to meet Annex 2 considerations at EU sites from January 2027 while the corresponding US position is still a draft. A practical approach is to design new protocols to the consolidated E6(R3) text where feasible, and to document in the trial master file which version of the guideline each region’s oversight relies on.

Protocol writers and medical writers should note that E6(R3) emphasises proportionality: quality should be built into trial design, and the intensity of oversight should match the risks to participants and to the reliability of results. Protocols, monitoring plans and data management plans that explain how critical-to-quality factors were identified are more likely to align with the revised guideline.